Tag: Hereditary Angioedema (HAE)

July 17, 2014 – The U.S. Food and Drug Administration (FDA) recently approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Hereditary angioedema, which is caused …

FDA approves the new product Ruconest (recombinant C1-Esterase inhibitor) to treat the rare genetic disease by the name of hereditary angioedema (HAE) Read more »